Tumor-specific adoptive T-cell therapy for CD40+ B-cell malignancies.
It is now widely accepted that current standard therapy does not lead to cure for the majority of patients with B-cell malignancies. In the search for novel treatment modalities and with the discovery of tumor-antigen--derived peptides recognized by T cells in the context of major histocompatibility complex class I and II molecules, active and passive immunotherapy has moved to center stage once again. Whereas most lymphoma research in this area has focused on vaccination strategies using the tumor-specific idiotype as a target antigen, this review focuses on the potential of a new strategy of adoptive transfer of antigen-specific T- for B-cell malignancies. Murine in vivo models and preclinical experiments suggest that we are now ready to enter the clinical arena to evaluate whether adoptive transfer of autologous or allogeneic antigen-specific T cells is a feasible and efficacious therapy approach for the treatment of B-cell malignancies. Potential obstacles to this strategy are also discussed.
Schultze
J L
JL
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Gribben
J G
JG
Nadler
L M
LM
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology* / Q000473:pathology; D019013:CD40 Antigens / Q000276:immunology*; D004195:Disease Models, Animal; D006801:Humans; D016219:Immunotherapy, Adoptive; D015448:Leukemia, B-Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000166:cytology / Q000276:immunology*
D019013:CD40 Antigens